These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia. McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858 [TBL] [Abstract][Full Text] [Related]
23. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Contacos C; Barter PJ; Vrga L; Sullivan DR Atherosclerosis; 1998 Nov; 141(1):87-98. PubMed ID: 9863541 [TBL] [Abstract][Full Text] [Related]
24. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
25. Fibrates: where are we now? Seth Loomba R; Arora R Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670 [TBL] [Abstract][Full Text] [Related]
26. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419 [TBL] [Abstract][Full Text] [Related]
27. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Adiels M; Matikainen N; Westerbacka J; Söderlund S; Larsson T; Olofsson SO; Borén J; Taskinen MR Atherosclerosis; 2012 May; 222(1):222-8. PubMed ID: 22365426 [TBL] [Abstract][Full Text] [Related]
28. Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors. Ballantyne CM Clin Cornerstone; 2007; 8 Suppl 6():S6-13. PubMed ID: 17948362 [TBL] [Abstract][Full Text] [Related]
29. The chylomicron saga: time to focus on postprandial metabolism. Gugliucci A Front Endocrinol (Lausanne); 2023; 14():1322869. PubMed ID: 38303975 [TBL] [Abstract][Full Text] [Related]
30. Influence of genetic factors in the modulation of postprandial lipemia. Perez-Martinez P; Lopez-Miranda J; Perez-Jimenez F; Ordovas JM Atheroscler Suppl; 2008 Sep; 9(2):49-55. PubMed ID: 18603482 [TBL] [Abstract][Full Text] [Related]
31. Evidence for a cholesteryl ester donor activity of LDL particles during alimentary lipemia in normolipidemic subjects. Lassel TS; Guerin M; Auboiron S; Guy-Grand B; Chapman MJ Atherosclerosis; 1999 Nov; 147(1):41-8. PubMed ID: 10525123 [TBL] [Abstract][Full Text] [Related]
32. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Oscarsson J; Hurt-Camejo E Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250 [TBL] [Abstract][Full Text] [Related]
33. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. Guerin M; Egger P; Le Goff W; Soudant C; Dupuis R; Chapman MJ J Clin Endocrinol Metab; 2002 Nov; 87(11):4991-5000. PubMed ID: 12414863 [TBL] [Abstract][Full Text] [Related]
34. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Reitsma JB; Castro Cabezas M; de Bruin TW; Erkelens DW Metabolism; 1994 Mar; 43(3):293-8. PubMed ID: 8139476 [TBL] [Abstract][Full Text] [Related]
37. Fibrates but not statins increase plasma selenium in dyslipidemic aged patients--the EVA study. Arnaud J; Akbaraly TN; Hininger-Favier I; Berr C; Roussel AM J Trace Elem Med Biol; 2009; 23(1):21-8. PubMed ID: 19203713 [TBL] [Abstract][Full Text] [Related]
38. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease. Karpe F; Hellénius ML; Hamsten A Metabolism; 1999 Mar; 48(3):301-7. PubMed ID: 10094104 [TBL] [Abstract][Full Text] [Related]
39. Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition. Föger B; Tröbinger G; Ritsch A; Lechleitner M; Hopferwieser T; Menzel HJ; Utermann G; Pfeiffer KP; Patsch JR Atherosclerosis; 1995 Oct; 117(2):253-61. PubMed ID: 8801871 [TBL] [Abstract][Full Text] [Related]
40. Management of diabetic dyslipidemia: need for reappraisal of the goals. Khera A; McGuire DK Am J Cardiovasc Drugs; 2005; 5(2):83-91. PubMed ID: 15725039 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]